CERTIFICATE OF ANALYSIS

Product Details

Product name:	Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab)	Lot.No.:	P247904
Target:	CTLA-4 / CD152, B7-H1 / PD-L1 / CD274	Catalog:	CHBA005
Target Accession:	P16410 & Q9NZQ7	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	VHH-VHH-Fc
Reactivity:	Human	Molecular Weight (kDa) :	107.44 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	＜1 EU/mg
Formulation:	Liquid：100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A

Data

MASS



The detected molecular weight of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 107.14 kDa.

Purity: SDS-PAGE



Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 97.11%, determined by SEC-HPLC.

ELISA



Erfonrilimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human CTLA4 Protein-His, and the EC50 was 0.010 nM.

Tel: +86 021 3368 1627 Email: service@sanyoubio.com Web: www.crs.sanyoubio.com

CERTIFICATE OF ANALYSIS

ISO 9001

ELISA



Erfonrilimab bound to PD-L1 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human PD-L1 Protein-His, and the EC50 was 0.012 nM.

Bioactivity: FACS



Erfonrilimab bound to huCTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huCTLA4-CHO-K cells, and the EC50 was 14.510 nM.

Bioactivity: FACS



Erfonrilimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.759 nM.

Function: Luciferase



Co-incubation of Erfonrilimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Erfonrilimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.681 nM.

Tel: +86 021 3368 1627 Email: service@sanyoubio.com Web: www.crs.sanyoubio.com